Testing the Targeted Therapy Elimusertib in Combination with Chemotherapy for Advanced Cancers identifier:
NCT04491942 (

Treatment study for people with advanced cancers

Study Contact Information:

For additional information, please contact:

Principal Investigator: Dr. Mamta Parikh
City of Hope Comprehensive Cancer Center


About the Study

This study is how well the drug elimusertib (a type of targeted therapy known as an ATR inhibitor) works when combined with chemotherapy for treating people with advanced cancers, including urothelial, ovarian, gastric, endometrial, triple-negative breast cancer and others.

This study is no longer enrolling people.

What the Study Involves

There will be two groups in this study. All participants will receive the study drug elimusertib. People will be assigned to a group based on their cancer type. 

Group 1: Ovarian, endometrial, triple-negative breast, urothelial, gastric, biliary tract, lung, head and neck

Group 2: Urothelial cancers only

After completion of study treatment, participants are followed up to 30 days, then every 3 months thereafter.

Study Sites:



New York




Ontario, Canada

This Study is Open To:

This study is no longer enrolling people.

This Study is Not Open To:

This study is no longer enrolling people.


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.